Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual ...

Summary of Phase 1 Zoldonrasib Data at AACR 2026 ( Abstract # CT021 ) ...

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and ...
Physician's Weekly

Emerging Therapeutic Approaches & Diagnostic Tools for Basal Cell Carcinoma

A recent narrative review looks at the most effective and emerging options for diagnosing and treating basal cell carcinoma.

New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...
The Manila Times

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...

New AI tool predicts whether aggressive small cell lung cancer will respond to treatment

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...
The New England Journal of Medicine

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
Medscape

Early Tislelizumab May Boost Progression-Free Survival in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, ...

Mom Who Never Smoked Given 12 Years to Live After Stage 4 Lung Cancer Diagnosis. 6 Years Later, 'There Is No Cancer'

Leah Phillips, a Kentucky mom of three, said she was initially told her symptoms were due to a cold, allergies or anxiety ...
Pharmabiz

Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer

Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...
PharmiWeb

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression ...

Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trialIf approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...